Fig. 5: Effect of metformin and anti-PD-L1 combination on immune cells antitumor activity towards NSCLC LKB1mut 3D tumor spheroids. | Cell Death & Disease

Fig. 5: Effect of metformin and anti-PD-L1 combination on immune cells antitumor activity towards NSCLC LKB1mut 3D tumor spheroids.

From: Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients

Fig. 5

A Bright-field images of LKB1mut H460 spheroids plated in culture 6 days after plating and treated with MET and anti-PD-L1 or anti-PD-1. Scale bars, 100 mm. B Representative IF images showing the infiltration ability of immune cells in 3D tumor spheroids of H460 cells. 3D tumor spheroids were blue stained, and the NSCLC patient-derived PBMCs were red stained. The PBMCs were treated with MET and anti-PD-L1 or anti-PD-1 for 48 h and added to 3D spheroids to start the co-culture. The co-localization of NSCLC cells and PBMCs is reported under the merge column. Scale bar 100 µm. C Evaluation of the red/blue intensity ratio as a quantitative indication of the colocalization rate of LC cells and PBMC. ****p < 0.0001. D Cell viability assay of PDTOs co-cultured for 48 h with MET, anti-PD-L1 or anti-PD-1 pre-treated NSCLC-patient derived PBMCs. Data are expressed as mean of three independent experiments ± SD. ****p < 0.0001.

Back to article page